Please try another search
For the fiscal year ended 31 March 2022, Fuso Pharmaceutical Industries Ltd revenues increased 1% to Y49.63B. Net income applicable to common stockholders decreased 8% to Y1.48B. Revenues reflect Rent Income Of Real Estate increase of 7% to Y175M. Net income was offset by Loss on retirement of non-current assets increase of 36% to Y15M (expense), Life insurance experses increase of 2% to Y99M (expense).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 11361 | 13305 | 12367 | 12599 |
Gross Profit | 3015 | 3603 | 3314 | 3465 |
Operating Income | -81 | 672 | 636 | 612 |
Net Income | -11 | 451 | 496 | 548 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 69334 | 70954 | 70575 | 69686 |
Total Liabilities | 34802 | 36366 | 36226 | 35937 |
Total Equity | 34532 | 34588 | 34349 | 33749 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 12 Months | 0 Months | 6 Months | 0 Months |
Cash From Operating Activities | 3497 | 1945 | ||
Cash From Investing Activities | -1553 | -610 | ||
Cash From Financing Activities | -1671 | 268 | ||
Net Change in Cash | 273 | 1603 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review